High-dose trimetrexate and minimal-dose leucovorin: A case for selective protection?

Clinical Cancer Research

Volumn 4, Issue 12, 1998, Pages 2981-2984

  Hum, Martina ^a   Holcenberg, John S ^b   Tkaczewski, Isabelle ^a   Weaver, Jill W ^a   Wilson, Jennifer ^a   Kamen, Barton A ^a,c  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLINIC ACID; TRIMETREXATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; CANCER GRADING; CHILD; CLINICAL ARTICLE; DOSE CALCULATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HUMAN; INFECTION PREVENTION; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; FEASIBILITY STUDIES; HUMANS; INFANT; LEUCOVORIN; LIVER FUNCTION TESTS; MUCOUS MEMBRANE; NEOPLASMS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIMETREXATE;

EID: 0032406717     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kamen, B. A. Folate and antifolate pharmacology. Semin Oncol., 24(S18): 30-39, 1997.
2. Kamen, B. A., Eible, B., Cashmore, A., and Bertino, J. R. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[3,4,5-trimethoxyanilino] methylquina-zoline), a non-classical antifolate in methotrexate resistant leukemia cells m vitro. Biochem. Pharmacol., 33: 1697-1699, 1984.
3. Trippelt, T., Schlemmer, S., Elisseyeff, Y., Goker, E., Wachter, M., Steinherz, P., Tan, C., Berman, E., Wright, J., Rosowsky, A., Schweitzer, B. I., and Bertino, J. R. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia. Blood, 80: 1158-1162, 1992.
4. Li, W-W., Lin, J. T., Schweitzer, B. I., Tong, W. P., Niedzwiecke, D., and Bertino, J. R. Intrinsic resistance to methotrexate in human soft tissue sarcoma cells. Cancer Res., 52: 3908-3913, 1992.
5. Li, W-W., Lin, J. T., Tong, W. P., Trippelt, T., Brennan, M. F., and Bertino, J. R. Mechanisms of natural resistance to anlifolales in human soft tissue sarcomas. Cancer Res., 52: 1434-1438, 1992.
6. Lacerda, J. F., Goker, E., Kheradpour, A., Dennig, D., Elisseyeff, Y., Jagiello, C., O'Reilly, R. J., and Bertino, J. R. Selective treatment of SCID mice bearing methotrexate transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin prolection. Blood, 58: 2675-2679, 1995.
7. Ohnuma, T., Lo, R. J., Scanlon, K., Kamen, B. A., Ohnoshi, T., Wolman, S. R., and Holland, J. F. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res., 45: 1815-1822, 1985.
8. Li, W-W., and Bertino, J. R. Inability of leucovorin to rescue a naturally methotrexate-resistant human soft tissue sarcoma cell line from trimetrexate toxicily. Cancer Res., 52: 6866-6870, 1992.
9. Allegra, C. J., Chabner, B. A., Tuazon, C. U., Ogata-Arakaki, D., Baird, B., Drake, J. C., Thayer Simmons, J., Lack, E. E., Shelhamer, J. H., Baus, F., Walker, R., Kovacs, J. A., Lane, C., and Mansur, H. Trimetrexate for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med., 317: 978-985, 1987.
10. Haller, D. G. Trimetrexate: experience with solid tumors. Semin. Oncol., 24(518): 71-76, 1997.
11. Tkaczewski, I., Tong, W. P., Spriggs, D., Bertino, J. R., Capizzi, R. L., and Kamen, B. A. Trimetrexate (TMTX) oral bioavailability and lack of cross resistance with HDMTX in patients with recurrent osteosarcoma (OS). Proc. Am. Soc. Clin. Oncol., 75: 475, 1996.
12. Kamen, B. A., Takach, P. L., Vatev, R., and Gaston, J. D. A rapid, radiochemical assay for methotrexate. Anal Biochem., 70: 54-63, 1976.
13. Kamen, B. A. Trimetrexate therapy for Pneumocystis carinii. Pediatr. Infect. Dis. J., 9: 215, 1990.
14. Stewart, J. A., McCormick, J. J., and Tong, W. P. Phase I clinical and pharmacokinetic study of trimetrexate using a daily X 5 schedule. Cancer Res., 48: 5029-5035, 1988.
15. Jolivet, J., Landry, L., Pinard, M. F., McCormick, J. J., Tong, W. P., and Eisenhauer, E. A. A phase I sludy of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections. Cancer Chemother. Pharmacol., 20: 169-172, 1987.
16. Fanucchi, M. P., Walsh, T. C., and Fleisher, M. Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. Cancer Res., 47: 3303-3308, 1987.
17. Hook, K. E., Nelson, J. M., Roberts, B. J., Griswold, D. P., and Leopold, W. R. Cell cycle effects of trimetrexate (CI-988). Cancer Chemother. Pharmacol., 16: 116-120, 1986.